Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Chimerix shares oral, IV data for brincidofovir
January 2017
SHARING OPTIONS:

DURHAM, N.C.—This year’s American Association of Pharmaceutical Scientists Annual Meeting saw Chimerix present data from a preclinical study of intravenous brincidofovir to determine tissue distribution after single IV or oral administration of the drug. The nucleotide analog has demonstrated in-vitro antiviral activity against all five families of DNA viruses that affect humans, including herpesviruses and adenoviruses, and has received Fast Track designation from the FDA for adenovirus, cytomegalovirus and smallpox. The data showed that oral administration of the drug offered consistent drug exposure to organs commonly targeted in viral infections, like the liver and kidney, and much higher exposure in the small intestine. The IV formulation offered much lower, but constant exposure to the small intestines and more consistent exposure levels to key organs. IV administration also caused high concentrations in the central nervous system.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.